Shen Liang, Cui Jing, Pang Ying-Xin, Ma Yan-Hui, Liu Pei-Shu
Department of Obstetrics and Gynaecology, Provincial Hospital Affiliated to Shandong University, Shandong, China.
Asian Pac J Cancer Prev. 2013;14(5):2915-8. doi: 10.7314/apjcp.2013.14.5.2915.
Recent studies have shown that 3-deazaneplanocin A (DZNep), a well-known histone methyltransferase inhibitor, disrupts polycomb-repressive complex 2 (PRC2), and induces apoptosis, while inhibiting proliferation and metastasis, in cancer cells, including acute myeloid leukemia, breast cancer and glioblastoma. However, little is known about effects of DZNep on ovarian cancer cells.
We here therefore studied DZNep-treated A2780 ovarian cancer cells in vitro. Proliferation of ovarian cancer cells under treatment of DZNep was assessed by MTT and apoptosis by flow cytometry. Cell wound healing was applied to detect the migration. Finally, we used q-PCR to assess the migration-related gene, E-cadherin.
DZNep could inhibit the proliferation of A2780 and induce apoptosis Furthermore, it inhibited migration and increased the expression of E-cadherin (P<0.05).
DZNep is a promising therapeutic agent for ovarian cancer cells, with potential to inhibite proliferation, induce apoptosis and decrease migration.
近期研究表明，3-去氮杂氮胞苷A（DZNep）作为一种著名的组蛋白甲基转移酶抑制剂，可破坏多梳抑制复合物2（PRC2），并在包括急性髓系白血病、乳腺癌和胶质母细胞瘤在内的癌细胞中诱导凋亡，同时抑制增殖和转移。然而，关于DZNep对卵巢癌细胞的影响知之甚少。
因此，我们在此研究了DZNep处理的体外培养的A2780卵巢癌细胞。通过MTT法评估DZNep处理下卵巢癌细胞的增殖情况，通过流式细胞术评估凋亡情况。采用细胞划痕愈合实验检测迁移能力。最后，我们使用q-PCR评估迁移相关基因E-钙黏蛋白。
DZNep可抑制A2780细胞的增殖并诱导凋亡。此外，它还抑制迁移并增加E-钙黏蛋白的表达（P<0.05）。
DZNep是一种有前景的卵巢癌细胞治疗药物，具有抑制增殖、诱导凋亡和减少迁移的潜力。
